MDS 2023 | TakeAim Leukemia: positive interim results regarding the efficacy of emavusertib in HR-MDS and AML
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses the ongoing TakeAim Leukemia (NCT04278768) Phase I/IIa study evaluating the efficacy of emavusertib monotherapy and in combination with azacitidine or venetoclax in patients with relapsed or refractory acute myeloid leukemia (R/R AML) or high-risk myelodysplastic syndromes (HR-MDS). Prof. Platzbecker notes that data analysis is still ongoing, but interim results have shown success in inducing remission in a subset of patients, including those with the FLT3 mutation. Prof. Platzbecker also notes that prior safety concerns regarding rhabdomyolysis have been resolved. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
